BSE Index Services Private Limited has announced the addition of Goldline Pharmaceutical Limited (Exchange Ticker: 544759) to the BSE SME IPO Index. The stock is being listed on BSE effective May 19, 2026, and will be included in the index at the open of May 20, 2026.

Key Points

• Goldline Pharmaceutical Limited (ticker: 544759) is newly listed on BSE effective May 19, 2026
• The stock will be added to the BSE SME IPO Index effective at open of May 20, 2026
• This addition is referenced from Notice No. 20260518-28
• The corporate action has been included in the end-of-day corporate action file (*.SDE) dated May 19, 2026
• Queries can be directed to bseindex@bseindia.com

Regulatory Changes

No regulatory changes. This is a routine index composition update following a new SME IPO listing.

Compliance Requirements

No direct compliance requirements for market participants. Index-tracking funds and ETFs benchmarked to the BSE SME IPO Index should update their portfolios to include Goldline Pharmaceutical Limited at the open of May 20, 2026.

Important Dates

• May 19, 2026: Goldline Pharmaceutical Limited listed on BSE
• May 20, 2026: Effective date of addition to BSE SME IPO Index (at market open)
• May 19, 2026 (end of day): Corporate action reflected in the *.SDE file

Impact Assessment

Limited market impact. This is a standard index inclusion event for a newly listed SME IPO stock. The primary impact is on passive funds and portfolios that track the BSE SME IPO Index, which will need to include this stock from May 20, 2026. No broader market or regulatory implications are expected.

BSE has announced that the equity shares of Goldline Pharmaceutical Limited (SME IPO, Scrip Code: 544759) will be transferred from the Trade for Trade segment (MT Group) to the Rolling segment (M Group) with effect from Wednesday, June 3, 2026. This notice is a continuation of Exchange Notice No. 20260518-28 dated May 18, 2026.

Key Points

• Equity shares of Goldline Pharmaceutical Limited (Scrip Code: 544759) will move from Trade for Trade (MT Group) to Rolling segment (M Group).
• Effective date of the segment transfer is Wednesday, June 3, 2026.
• This is a continuation of Notice No. 20260518-28 dated May 18, 2026.
• Department: DCS-Listing; Segment: SME.
• Contact person for queries: Mr. Anurag Jain, Tel. No. 022-2272 8822.

Regulatory Changes

The trading classification of Goldline Pharmaceutical Limited equity shares is being changed from the Trade for Trade settlement segment (MT Group) to the Rolling settlement segment (M Group). This change alters the settlement mechanism applicable to trades in this scrip.

Compliance Requirements

• Trading Members must note the change in settlement segment effective June 3, 2026.
• Members should update their systems and processes to reflect the new M Group classification for Scrip Code 544759.
• For further clarifications, Trading Members may contact Mr. Anurag Jain at Tel. No. 022-2272 8822.

Important Dates

• May 18, 2026: Original notice (No. 20260518-28) issued.
• May 19, 2026: Continuation notice issued.
• June 3, 2026: Effective date for transfer from MT Group (Trade for Trade) to M Group (Rolling segment).

Impact Assessment

This segment migration is a standard transition for SME IPO stocks after the mandatory Trade for Trade period. Moving to Rolling settlement (M Group) increases liquidity and trading flexibility for investors, as trades will now be settled on a net basis rather than gross trade-for-trade basis. Trading members dealing in this scrip should update their risk and settlement systems accordingly before June 3, 2026. The impact is moderate and limited to participants trading Goldline Pharmaceutical Limited shares.